Inventor · disambiguated record
Christos Kyratsous
Also filed as: KYRATSOUS CHRISTOS · KYRATSOUS CHRISTOS A
36 granted patents·34 pending applications·399 citations·filing 2010–2025
97Inventor score
Files withREGENERON PHARMA60INTELLIA THERAPEUTICS INC4DECIBEL THERAPEUTICS INC3C/O REGENERON PHARMACEUTICALS INC1SILVERSTEIN SAUL J1
Top patents by PatentIndex Score
70 records- 0197US10975139B1Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Apr 13, 2021·15 cites·20 claims
- 0297US10954289B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Mar 23, 2021·28 cites·28 claims
- 0397US10787501B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Sep 29, 2020·224 cites·20 claims
- 0496US11530255B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2020·Granted Dec 20, 2022·3 cites·18 claims
- 0596US9771414B2Human antibodies to ebola virus glycoproteinREGENERON PHARMA·Filed 2016·Granted Sep 26, 2017·18 cites·32 claims
- 0695US11208458B2Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2018·Granted Dec 28, 2021·28 cites·20 claims
- 0794US10501526B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2018·Granted Dec 10, 2019·11 cites·13 claims
- 0894US9718872B2Human antibodies to middle east respiratory syndrome—coronavirus spike proteinREGENERON PHARMA·Filed 2015·Granted Aug 1, 2017·18 cites·25 claims
- 0993US11732030B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·51 claims
- 1093US11259510B2Humanized T cell mediated immune responses in non-human animalsREGENERON PHARMA·Filed 2016·Granted Mar 1, 2022·8 cites·31 claims
- 1193US10081670B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2017·Granted Sep 25, 2018·10 cites·13 claims
- 1292US10421804B2Anti-Zika virus antibodies and methods of useREGENERON PHARMA·Filed 2017·Granted Sep 24, 2019·11 cites·24 claims
- 1391US10829544B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2019·Granted Nov 10, 2020·2 cites·20 claims
- 1490US11117955B2Anti-Zika virus antibodies and methods of useREGENERON PHARMA·Filed 2019·Granted Sep 14, 2021·4 cites·18 claims
- 1588US12252520B2Myosin 15 promoters and uses thereofDECIBEL THERAPEUTICS INC·Filed 2021·Granted Mar 18, 2025·2 cites·13 claims
- 1688US9497945B2Humanized dipeptidyl peptidase IV (DPP4) animalsREGENERON PHARMA·Filed 2015·Granted Nov 22, 2016·5 cites·30 claims
- 1786US12251440B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·16 claims
- 1886US9532555B2Humanized dipeptidyl peptidase IV (DPP4) animalsREGENERON PHARMA·Filed 2015·Granted Jan 3, 2017·4 cites·15 claims
- 1985US10406222B2Human antibodies to Middle East Respiratory Syndrome—coronavirus spike proteinREGENERON PHARMA·Filed 2017·Granted Sep 10, 2019·4 cites·11 claims
- 2083US12152067B2Human antibodies to ebola virus glycoproteinREGENERON PHARMA·Filed 2022·Granted Nov 26, 2024·0 cites·57 claims
- 2181US11377502B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 5, 2022·1 cites·5 claims
- 2280US2025171520A1Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2376US10212923B2Humanized dipeptidyl-peptidase IV (DPP4) animalsREGENERON PHARMA·Filed 2016·Granted Feb 26, 2019·1 cites·24 claims
- 2475US12256720B2Humanized dipeptidyl-peptidase IV (DPP4) animalsREGENERON PHARMA·Filed 2021·Granted Mar 25, 2025·0 cites·5 claims
- 2575US2024301442A1Methods and compositions for insertion of antibody coding sequences into a safe harbor locusREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2674US12215138B2Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2021·Granted Feb 4, 2025·0 cites·24 claims
- 2774US2023345919A1Non-human animals comprising a humanized asgr1 locusREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2874US2024343831A1Anti-tmprss2 antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2973US11013220B2Humanized dipeptidyl-peptidase IV (DPP4) animalsREGENERON PHARMA·Filed 2019·Granted May 25, 2021·0 cites·7 claims
- 3072US2024083983A1Anti-hemagglutinin antibodies and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3171US2025255940A1Compositions and methods for expressing factor ixINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3270US2024301041A1Anti-staphylococcus antibodies and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3369US12496470B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2022·Granted Dec 16, 2025·0 cites·20 claims
- 3468US12497460B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Dec 16, 2025·0 cites·30 claims
- 3568US2024252601A1Ace2 fusion proteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3667US11999799B2Anti-TMPRSS2 antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2021·Granted Jun 4, 2024·0 cites·44 claims
- 3767US2022174921A1Humanized t cell mediated immune responses in non-human animalsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3866US11773156B2Anti-hemagglutinin antibodies and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Oct 3, 2023·0 cites·21 claims
- 3966US2024287162A1Multivalent anti-spike protein binding molecules and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4066US2024309072A1Multivalent anti-spike protein binding molecules and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4166US2024307512A1ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOFREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4265US12410442B2Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systemsDECIBEL THERAPEUTICS INC·Filed 2021·Granted Sep 9, 2025·0 cites·19 claims
- 4364US12459991B2Compositions and methods for using bispecific antibodies to bind complement and a target antigenREGENERON PHARMA·Filed 2020·Granted Nov 4, 2025·0 cites·7 claims
- 4464US2025302998A1Vectors and methods for in vivo antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4563US12024556B2Anti-Staphylococcus antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 2, 2024·0 cites·4 claims
- 4662US12214023B2Compositions and methods for expressing factor IXINTELLIA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·0 cites·16 claims
- 4762US11696572B2Non-human animals comprising a humanized ASGR1 locusREGENERON PHARMA·Filed 2018·Granted Jul 11, 2023·0 cites·25 claims
- 4861US2025049006A1Non-human animals comprising humanized ace2 and tmprss lociC/O REGENERON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4960US2024316169A1Utilization of antibodies to shape antibody responses to an antigenREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 5060US2025304637A1Myosin 15 promoters and uses thereofDECIBEL THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Christos Kyratsous files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →